zambia herald : Latest News and In-depth Analysis
SEOUL,South Korea,Feb. 13,2025 -- DAAN Biotherapeutics,a leading innovative drug development company specializing in T-cell receptor (TCR)- based therapies,has signed an exclusive licensing agreement with LigaChem Biosciences for a novel tumor-targeting antibody to advance the development and commercialization of Antibody-Drug Conjugates (ADC).
By leveraging DAAN Biotherapeutics' next-generation antibody technology,built upon its exceptional target discovery and antibody development capabilities,LigaChem Biosciences is now positioned to take a significant step forward in ADC development for solid tumor patients.
DAAN Biotherapeutics has successfully established a proprietary pipeline for efficiently developing antibodies targeting overexpressed tumor targets in solid cancers through a strategic partnership with OmniAb.
Byoung Chul Cho,MD,the CEO of DAAN Biotherapeutics,stated,"We will continue to develop state-of-the-art antibodies targeting solid tumors and collaborate with global pharmaceutical companies in the ADC field. Beyond ADCs,we also aim to become a global leader in solid tumor-targeting T-cell engagers using our proprietary TACTIC (Tumor Targeting Conditionally Activated T Cell Engager) platform."
The mum of a lab worker who died in Siberia has spoken out (Picture: Daria Shipilova/e2w) The mother of a scientist who died after contracting a suspected case of pneumonic plague in Russia has spoke
A rare baby turtle has been discovered with two heads — and seemingly two distinct personalities.
An Aeroflot A321, named after Russian soprano Galina Vishnevskaya, has been parked at Geneva Airport since 2022.
Lyudmila was killed by a brown bear outside her house (Pictures: east2west news) A woman in her sixties was mauled to death by a brown bear outside her home on the edge of a remote forest.
